Chinese inhibitor drug candidate becomes first to enter phase -Stellar Signals news portal

当前位置：首页 >business >Chinese inhibitor drug candidate becomes first to enter phase

Chinese inhibitor drug candidate becomes first to enter phase

Release time：2024-06-03 21:10:08 Source：Stellar Signals news portal

Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.

SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.

The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.

The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.

Random recommendation

Indonesia’s Ruang volcano spews more hot clouds after eruption forces closure of schools, airports Japan's Kishida will stress rules FAFSA financial aid rollout leaves college dreams in limbo Lawmakers want the Chiefs and Royals to come to Kansas, but a stadium plan fizzled Nonstop Mideast coverage of Israel Ford recalls Maverick pickups in US because tail lights can go dark, increasing the risk of a crash How AI is facing its 'Oppenheimer moment'How you could be allergic to your glass of wine Ecuador defends raid on the Mexican Embassy and tells top UN court it acted to take in a criminal Man makes shocking 100